Can I Take Vitamin D with Viagra (Sildenafil)?

The Short Answer: No Dangerous Interaction

Vitamin D and sildenafil do not share metabolic enzymes, protein-binding sites, or physiological targets in a way that creates a clinically meaningful drug-supplement interaction. The FDA prescribing information for sildenafil lists no interaction with vitamin D or any vitamin D analog [1]. Likewise, the Endocrine Society's 2011 clinical practice guideline on vitamin D deficiency does not flag PDE5 inhibitors as a concern [2].

Why Absence of Interaction Matters for PDE5 Inhibitors

Sildenafil is metabolized primarily by CYP3A4 (major) and CYP2C9 (minor) in the liver [1]. Drugs that inhibit CYP3A4, such as ketoconazole or ritonavir, raise sildenafil plasma concentrations substantially, which is why those combinations require dose reduction. Vitamin D3 (cholecalciferol) is hydroxylated to 25-OH-D in the liver by CYP2R1 and CYP27A1, then converted to the active 1,25-dihydroxyvitamin D (calcitriol) by CYP27B1 in the kidney [3]. None of these enzymes overlap with sildenafil's metabolic pathway. There is no competitive inhibition, no induction of clearance, and no displacement from plasma proteins.

What the Interaction Databases Say

The Natural Medicines Database rates the vitamin D and sildenafil combination as having no known interaction. Mayo Clinic's drug interaction checker returns no flag for this pairing. Neither finding should be interpreted as a blanket license to combine any supplement with Viagra. It simply means that for vitamin D specifically, the pharmacology does not support a mechanism for harm.

How Sildenafil Works and Why Vascular Health Matters

Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5), preventing the degradation of cyclic GMP (cGMP) in penile smooth muscle. Elevated cGMP relaxes smooth muscle, increases arterial inflow, and produces an erection in the presence of sexual stimulation [1]. The drug does not generate cGMP on its own; nitric oxide (NO) released from endothelial cells and nerve terminals does that first. This dependence on endothelial function means sildenafil works best when vascular health is intact.

Endothelial Function Is the Common Variable

Low vitamin D status is associated with impaired endothelial function, reduced nitric oxide bioavailability, and increased arterial stiffness [4]. A 2018 meta-analysis published in Atherosclerosis (pooling 19 trials, N=1,812) found that vitamin D supplementation improved flow-mediated dilation by a mean of 2.3% compared with placebo (P<0.001) [4]. Flow-mediated dilation is a surrogate marker for the endothelial NO pathway that sildenafil depends on. Correcting a deficiency may therefore create a more favorable physiological environment for PDE5 inhibition, though this is an indirect relationship rather than a direct pharmacological combination.

Nitric Oxide, Vitamin D, and the eNOS Pathway

Calcitriol (1,25-dihydroxyvitamin D) upregulates endothelial nitric oxide synthase (eNOS) gene expression in vascular endothelial cells, according to in vitro data published in Circulation Research [5]. ENOS is the enzyme that produces the nitric oxide that starts the cGMP cascade sildenafil depends on. Whether oral vitamin D supplementation at standard doses replicates this effect in vivo at clinically meaningful concentrations is not yet established by large randomized controlled trials. The mechanistic signal, however, is biologically plausible.

Vitamin D Deficiency Is Common in Men with ED

This is the most actionable part of the clinical picture. Men presenting with erectile dysfunction have measurably lower 25-OH-D levels compared with controls in multiple observational studies.

Prevalence Data

A cross-sectional analysis using NHANES 2001-2004 data found that 41.6% of U.S. Adults were vitamin D deficient (25-OH-D <20 ng/mL), with Black men showing rates above 82% [6]. In a separate study published in the Journal of Sexual Medicine (N=3,390 men, mean age 56 years), men with severe vitamin D deficiency had a 32% higher odds of ED after controlling for age, BMI, smoking, and cardiovascular comorbidities [7]. That is an independent association, not proof of causation.

Does Correcting Deficiency Improve Erections?

A randomized controlled trial published in the Journal of Urology (N=102 men with ED and 25-OH-D <20 ng/mL) assigned participants to vitamin D3 3,000 IU/day or placebo for 12 months [8]. At 12 months, the supplementation group showed a 4.1-point improvement in the International Index of Erectile Function-5 (IIEF-5) score versus 1.2 points in the placebo arm (P<0.05) [8]. An IIEF-5 improvement of 4 points is considered clinically meaningful. This does not mean vitamin D replaces sildenafil. It suggests that for men who are deficient, repletion may improve baseline erectile function independently of PDE5 inhibition.

The HealthRX Clinical Decision Framework: Vitamin D + Sildenafil

The table below summarizes the recommended workup approach for men starting or already using sildenafil.

| Step | Action | Threshold / Detail | |------|--------|--------------------| | 1 | Measure serum 25-OH-D | At baseline before or shortly after starting sildenafil | | 2 | Classify status | Deficient <20 ng/mL, insufficient 20-29 ng/mL, sufficient 30-100 ng/mL | | 3 | Replete if deficient | 50,000 IU vitamin D3 weekly x 8 weeks, then maintenance 1,500-2,000 IU/day | | 4 | Continue sildenafil as prescribed | No dose adjustment needed; no timing restriction with vitamin D | | 5 | Recheck 25-OH-D | At 3 months post-repletion | | 6 | Address comorbidities | Hypertension, dyslipidemia, metabolic syndrome all worsen both ED and vitamin D status |

Pharmacokinetic Profile of Sildenafil: What Actually Causes Interactions

Understanding what does interact with sildenafil helps clarify why vitamin D does not.

CYP3A4 Inhibitors and Inducers

Sildenafil's plasma half-life is approximately 4 hours. Co-administration with potent CYP3A4 inhibitors significantly raises area under the curve (AUC). The FDA prescribing label states that ritonavir increases sildenafil AUC by 11-fold, and the combination is contraindicated in pulmonary arterial hypertension dosing [1]. Erythromycin raises sildenafil AUC approximately 182%. Grapefruit juice, a moderate CYP3A4 inhibitor, raises sildenafil AUC by up to 23% and is generally advised to avoid on dosing days [1]. Vitamin D produces none of these effects.

Nitrate Contraindication

The only absolute contraindication with sildenafil is concurrent nitrate use (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite). Both sildenafil and organic nitrates lower blood pressure through cGMP-related pathways, and the combination can produce severe, life-threatening hypotension [1]. This is completely unrelated to vitamin D.

Alpha-Blocker Caution

Alpha-blockers (tamsulosin, doxazosin) combined with sildenafil may cause additive hypotension. The prescribing label recommends starting sildenafil at 25 mg if an alpha-blocker is already established in the regimen [1]. Again, vitamin D has no vasodilatory mechanism and raises no similar concern.

Vitamin D Toxicity: When Supplementation Itself Becomes a Risk

Vitamin D is fat-soluble and accumulates. Toxicity is rare at standard doses but real at very high doses sustained over time.

The Safe Supplementation Window

The Endocrine Society's clinical practice guideline states that 25-OH-D levels above 150 ng/mL are associated with toxicity, and levels above 100 ng/mL should trigger evaluation [2]. As the guideline authors wrote: "Screening for vitamin D deficiency should be done in patients at risk, and treatment with either vitamin D2 or vitamin D3 is recommended to achieve a level of at least 30 ng/mL" [2]. Daily doses of 1,500-2,000 IU in adults maintain sufficiency in most people. The tolerable upper intake level set by the Institute of Medicine is 4,000 IU/day for adults, though many clinicians use doses above this for limited repletion periods under monitoring [9].

Hypercalcemia and Cardiac Rhythm

Severe vitamin D toxicity causes hypercalcemia, which can produce QT interval changes and cardiac arrhythmias. Sildenafil itself does not affect the QT interval at therapeutic doses in healthy subjects. But hypercalcemia from toxic vitamin D doses combined with sildenafil's mild vasodilatory effects could theoretically compound hemodynamic instability. This scenario requires doses well above any reasonable therapeutic range. It is not a reason to avoid standard vitamin D supplementation alongside sildenafil.

Cardiovascular Context: Who Is Taking Sildenafil?

Men who use sildenafil for ED often have underlying cardiovascular risk factors. ED is now recognized as an early marker of cardiovascular disease. The Massachusetts Male Aging Study found that ED prevalence rises from roughly 5% at age 40 to 15% at age 70 [10]. Cardiovascular disease is the most common identifiable systemic cause.

Vitamin D Status and Cardiovascular Risk

A Mendelian randomization study published in The Lancet Diabetes and Endocrinology (N=267,980 participants with genetic data) found that genetically predicted higher vitamin D status was associated with lower risk of all-cause mortality and cardiovascular disease in participants with baseline 25-OH-D below 25 nmol/L [11]. This causal inference approach reduces confounding from observational studies. For men with ED who also carry cardiovascular risk, optimizing vitamin D status is clinically reasonable independently of any interaction with sildenafil.

The VITAL Trial

The VITAL randomized controlled trial (N=25,871, median follow-up 5.3 years) tested vitamin D3 2,000 IU/day against placebo for cardiovascular and cancer outcomes [12]. Supplementation did not significantly reduce major cardiovascular events overall. In subgroup analyses, participants with BMI below 25 showed a more favorable cardiovascular response. The trial did not measure erectile function. Its relevance here is that it established 2,000 IU/day as a safe long-term dose in a large, well-monitored population [12].

Drug Interactions You Should Actually Worry About with Sildenafil

To give proper context, the interactions that genuinely matter with sildenafil are worth listing clearly.

High-Priority Contraindications and Cautions

Organic nitrates in any form are absolutely contraindicated [1]. Soluble guanylate cyclase stimulators such as riociguat are also contraindicated because the combination produces profound hypotension [1]. Potent CYP3A4 inhibitors (ritonavir, atazanavir, ketoconazole, itraconazole, clarithromycin) require dose reduction to 25 mg and less frequent dosing [1]. Men taking any of these should discuss sildenafil dosing carefully with their prescribing clinician before adding any supplement, even a benign one, to their regimen.

Supplements That May Interact with Sildenafil

A handful of supplements carry moderate interaction signals worth noting. L-arginine, a nitric oxide precursor, may augment sildenafil's vasodilatory effect and increase hypotension risk at high doses. Yohimbe (yohimbine) may increase blood pressure and is not recommended alongside sildenafil. St. John's Wort induces CYP3A4 and can reduce sildenafil plasma concentrations by up to 70%, potentially reducing efficacy [13]. Vitamin D belongs in none of these categories.

Monitoring Checklist for Men Taking Both

Practical monitoring for a man taking sildenafil and vitamin D simultaneously should follow these points.

Check serum 25-OH-D within the first few weeks of starting sildenafil if not recently measured. Treat documented deficiency per Endocrine Society protocol [2]. Recheck 25-OH-D at 3 months. Do not exceed 4,000 IU/day without physician supervision unless a formal repletion course has been prescribed. Report any new symptoms of hypercalcemia (nausea, weakness, polyuria, confusion) to a clinician promptly, even though these are very unlikely at standard doses.

Sildenafil dosing is unaffected by vitamin D status. Start at 50 mg and adjust based on efficacy and tolerability, not on vitamin D levels.

What Happens If You Are Already Taking Both

Nothing special happens. Men who are already taking both vitamin D and sildenafil do not need to stop, separate doses, or seek an urgent clinical review based on this combination alone. The rational step is confirming that vitamin D status has been measured and that the dose used falls within safe parameters. If 25-OH-D has never been checked, ordering a level is a reasonable quality-of-care step during any routine follow-up.

A 2021 cross-sectional study in the American Journal of Men's Health (N=468 men on PDE5 inhibitors) found that fewer than 28% had received a vitamin D level check in the preceding 24 months, despite 44% of the cohort being deficient [14]. Routine screening in this population is underutilized.